Date Title and Summary Additional Formats
November 10, 2021
SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2021, together with
November 2, 2021
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following virtual investor conferences during the month of November.
October 13, 2021
SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2021 financial and operating results after the market closes on
October 7, 2021
Advancement Expected to Further Accelerate Development of mRNA Vaccines and Therapeutics SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that the
October 4, 2021
EyeGene expected to utilize TriLink’s CleanCap® technology and modified UTP manufactured by TriLink in the production of its EG-COVID mRNA COVID-19 vaccine for clinical trials SAN DIEGO , Oct. 04, 2021 (GLOBE NEWSWIRE) -- TriLink BioTechnologies (“TriLink”), a Maravai LifeSciences company (Nasdaq:
September 10, 2021
SAN DIEGO, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI) , a global provider of life science reagents and services to researchers and biotech innovators, today announced the pricing of a public offering of 20,000,000 shares of Maravai’s
September 7, 2021
SAN DIEGO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI) , a global provider of life science reagents and services to researchers and biotech innovators, today announced the commencement of a public offering of its Class A common stock by
September 7, 2021
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following virtual investor conferences during the month of September.
August 10, 2021
SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2021, together with other
August 2, 2021
TriLink enables Chula VRC to take its Covid-19 vaccine into a First in Human (FIH) phase 1 clinical trial in Thailand with mRNA manufacturing process development and its proprietary mRNA capping technology, ushering a much-needed vaccine into economically developing countries SAN DIEGO, Aug.
Displaying 1 - 10 of 24